Bikeattitude

Freeride

Vous n'êtes pas identifié.

#1 2019-08-09 20:54:03

goon2019
Member
Date d'inscription: 2019-05-08
Messages: 401

Federal jury convicts east Idaho man on anabolic steroid charges

Federal jury convicts east Idaho man on anabolic steroid charges


A federal jury in Pocatello convicted Travis M. Newbold, 47, on Friday, of conspiracy to import anabolic steroids, importation of anabolic steroids, and possession with intent to distribute anabolic steroids, U.S. Attorney Bart M. Davis announced. Newbold was charged by indictment on Nov. 28, 2017.<a href="https://www.buyaas.com/nolvadex-to-treat-breast-cancer/">Nolvadex dosage</a>

According to the evidence presented at trial, on Oct. 25, 2017, investigators from Homeland Security Investigations, U.S. Postal Inspection Service, and Pocatello Police Department conducted a controlled delivery of a package that was destined for Newbold’s address. The package contained over three pounds of powdered anabolic steroids.

Investigators searched Newbold’s home that day pursuant to a search warrant. They found over three pounds of additional anabolic steroid powders, liquid vials of anabolic steroids, recipes for making oral and injectable anabolic steroids, and other steroid dispensing paraphernalia. A search of Newbold’s phone revealed that he was ordering the anabolic steroids from China, and helping to trans-ship packages for a China-based anabolic steroid supplier.

Sentencing is set for Jan. 10 at 1:30 p.m. in Pocatello before the Chief U.S. District Judge B. Lynn Winmill. Newbold faces up to ten years’ imprisonment, a $1,000,000 fine, and at least three years supervised release.

“I want to thank the agencies and dedicated law enforcement officers who helped bring this case to trial,” said U.S. Attorney Davis. “Helping to ban the flow of illegal imported drugs into Idaho is a high priority to our office. We are proud the partnership with local and federal law enforcement yielded a conviction in this important case.”
“The United States Postal Inspection Service is dedicated to enforcing the laws that defend the nation’s mail system from illegal or dangerous use and ensure public trust in the mail by holding those persons accountable who attempt to utilize the United States Postal Service to traffic illicit controlled substances,” said Anthony Galetti, Postal Inspector in Charge for the Seattle Division of U.S. Postal Investigation Service.

“The international importation of these dangerous performance-enhancing drugs pose a serious public health and safety risk to our community,” said Brad Bench, Special Agent in Charge of Homeland Security Investigations Seattle. “We are proud to be part of the group of highly-motivated, professional agents and law enforcement partners who have worked to remove these hazardous, unregulated substances from our streets.”

“The teamwork of the police officers and the federal partners has been outstanding,” said Pocatello Police Sergeant Nathan Diekemper. “We applaud the diligent efforts of the prosecutors and public servants who helped obtain this conviction. Pocatello is a safer place through this combined effort.”

This case was investigated through the combined efforts of the Department of Homeland Security, the U.S. Postal Inspection Service, the Pocatello Police Department, the U.S. Attorney’s Office and the Eastern Idaho Partnership. The Eastern Idaho Partnership is a collaborative effort among local communities, law enforcement, the State of Idaho, and the U.S. Attorney for the District of Idaho. The Partners combine efforts to fund and support a Special Assistant United States Attorney, or “SAUSA.” The SAUSA, Bryan Wheat, works with local prosecutors and law enforcement to prosecute serious local crimes in federal court. The Partnership focuses its efforts on regional drug trafficking, gun and gang violence, internet based crimes against children, and other serious crimes with a federal nexus that affect the southeast Idaho region.

Hors ligne

 

#2 2019-08-09 20:58:22

goon2019
Member
Date d'inscription: 2019-05-08
Messages: 401

Re: Federal jury convicts east Idaho man on anabolic steroid charges

Low-Dose Tamoxifen Halves Breast Cancer Risk in Women With Preinvasive Breast Lesions


5 mg/d, given for 3 years rather than 5 years—halved the risk of breast cancer recurrence or new lesions over placebo in women with breast intraepithelial neoplasia, without producing the usual toxicities seen with the standard dose, Italian researchers reported at the 2018 San Antonio Breast Cancer Symposium.1
“We believe our results have external validity and—given their pragmatic nature and the easy accessibility of tamoxifen—are generalizable,” said Andrea De Censi, MD, of the National Hospital E.O. Ospedali Galliera–Division of Medical Oncology in Genoa, Italy. “Tamoxifen, 5 mg a day (splitting the tablet) or 10 mg every other day, is applicable in clinical practice tomorrow.”Nolvadex dosage

Breast cancer experts at the meeting said this is news they can use. “Looking at these data, I would definitely give lower doses of tamoxifen, especially in patients with atypical ductal hyperplasia and lobular carcinoma in situ,” said Virginia G. Kaklamani, MD, Professor of Medicine at The University of Texas at San Antonio and leader of the Breast Cancer Program at The University of Texas MD Anderson Cancer Center, Houston.
This information tells me I can perhaps cut back on the dose for patients who are not tolerating tamoxifen. This would help me keep them on the dose, rather than have them abandon therapy,” said John Cole, MD, of the Ochsner Health System in New Orleans.

ALTHOUGH TAMOXIFEN is effective in preventing breast cancer recurrence, its side effects—menopausal symptoms, endometrial cancer, deep-vein thrombosis, and pulmonary embolism— are barriers for its use as a preventive measure. The aim of this de-escalation study was to determine whether a lower dose and shorter duration of tamoxifen therapy would be as efficacious as and better tolerated than the standard dose.

Dr. De Censi and colleagues had previously shown that a dose as low as 1 mg/d is noninferior to 20 mg in decreasing Ki67 (a marker of proliferation), though less effective in modulating serum biomarkers.2 For the current study, the investigators decided 5 mg/d would be a reasonable compromise between activity and safety. He explained that the government- and charity-funded study could not afford to financially support the use of a very large noninferiority trial of tamoxifen at 20 mg/d for 5 years as the control arm.

Hors ligne

 

Pied de page des forums

Propulsé par FluxBB
Traduction par FluxBB.fr